4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pseudomonas aeruginosa Implant-Associated Bone and Joint Infections: Experience in a Regional Reference Center in France

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: P. aeruginosa implant-associated bone and joint infections (BJI) is considered to be one of the most difficult to treat BJI. The data focusing specifically on this pathogen are sparse, and it seems difficult to extrapolate the results obtained with Enterobacteriaceae.

          Methods: We performed a retrospective observation study of all P. aeruginosa implant-associated BJI diagnosed at our institution from 2011 to 2018. We defined failure as any type of relapse, including persistence of the same P. aeruginosa, superinfection by another organism(s) or any other cause of relapse such as the need for a subsequent surgery. Nonparametric statistical methods were used to compare the study groups and Kaplan-Meier curves and multivariate Cox analysis and were used to detect determinants associated with treatment failure.

          Results: A total of 90 patients (62% men, median age 60 years IQR 47–72) including 30 (33%) prosthetic-joint infections and 60 (66%) other implant-associated BJIs were studied. Most of them were acute (62%). During the prolonged follow-up, (median 20 months; IQR 9–37), 23 patients (26%) experienced treatment failure. Optimal surgical treatment (DAIR for acute forms, explantation, 1-stage or 2-stage exchange for others) was significantly associated with a higher success rate in the univariate analysis ( p = 0.003). Sixty-four (71%) patients received effective initial treatment against P. aeruginosa administered and 81 of them (90%) did for at least 3 weeks: both these parameters correlated with a higher success rate. In the multivariate Cox-analysis optimal surgical treatment, IV effective treatment of at least 3 weeks and treatment with ciprofloxacin for at least 3 months proved to be independently associated to a better outcome in patients with P. aeruginosa implant-associated BJI.

          Conclusion: P. aeruginosa implant-associated BJI is one of the most difficult-to-treat BJI, with a strong impact on the prognosis of the surgical strategy. An effective initial IV antibiotic treatment for at least 3 weeks seems to be required, followed by oral ciprofloxacin for a total duration of 3 months.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.

          These guidelines are intended for use by infectious disease specialists, orthopedists, and other healthcare professionals who care for patients with prosthetic joint infection (PJI). They include evidence-based and opinion-based recommendations for the diagnosis and management of patients with PJI treated with debridement and retention of the prosthesis, resection arthroplasty with or without subsequent staged reimplantation, 1-stage reimplantation, and amputation.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Prosthetic-joint infections.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The challenge of treating biofilm-associated bacterial infections.

              Biofilm formation is a crucial step in the pathogenesis of many subacute and chronic bacterial infections, including foreign body-related infections. Biofilms are difficult to eradicate with conventional antimicrobial agents. Bacterial biofilms have several potential antimicrobial resistance mechanisms. Antimicrobial resistance mechanisms may act concurrently, and in some cases, synergistically. Persister cells play a major role in the tolerance of biofilm bacteria to antimicrobial agents. Understanding the mechanisms involved in biofilm-associated antimicrobial resistance is key to development of new therapeutic strategies.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Med (Lausanne)
                Front Med (Lausanne)
                Front. Med.
                Frontiers in Medicine
                Frontiers Media S.A.
                2296-858X
                26 October 2020
                2020
                : 7
                : 513242
                Affiliations
                [1] 1Hospices Civils de Lyon , Lyon, France
                [2] 2Université Claude Bernard Lyon 1 , Lyon, France
                [3] 3Centre Interrégional de Référence des Infections Ostéo-articulaires complexes (CRIOAc Lyon), Hospices Civils de Lyon , Lyon, France
                [4] 4Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1 , Lyon, France
                Author notes

                Edited by: Murat Akova, Hacettepe University, Turkey

                Reviewed by: Guangqiang Wang, University of Shanghai for Science and Technology, China; Werner Zimmerli, Cantonal Hospital Baselland (KSBL), Switzerland; Gennaro De Pascale, Catholic University of the Sacred Heart, Italy

                *Correspondence: Tristan Ferry tristan.ferry@ 123456univ-lyon1.fr

                This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine

                Article
                10.3389/fmed.2020.513242
                7649271
                33195289
                8de746ad-9a27-4d16-9aac-8ca8e709956c
                Copyright © 2020 Cerioli, Batailler, Conrad, Roux, Perpoint, Becker, Triffault-Fillit, Lustig, Fessy, Laurent, Valour, Chidiac, Ferry.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 19 November 2019
                : 22 September 2020
                Page count
                Figures: 1, Tables: 2, Equations: 0, References: 40, Pages: 7, Words: 5754
                Categories
                Medicine
                Original Research

                pseudomonas,osteomyelitis,ciprofloxacin,implant-associated bone infections (iabi),bone and joint infection

                Comments

                Comment on this article